Liquidia Stock (NASDAQ:LQDA)
Previous Close
$89.03
52W Range
$16.82 - $91.10
50D Avg
$70.49
200D Avg
$43.39
Market Cap
$7.67B
Avg Vol (3M)
$1.95M
Beta
0.55
Div Yield
-
LQDA Company Profile
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.